{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.ai-analytics.org/api/v1/entity/IONS/timeline","_source":{"data_provider":"AI Analytics","data_provider_url":"https://api.ai-analytics.org","license":"https://api.ai-analytics.org/license","usage_info":"https://api.ai-analytics.org/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-09-22T11:59:01.156Z","methodology_url":"https://api.ai-analytics.org/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":8828,"canonical_name":"IONIS PHARMACEUTICALS INC","cik":"0000874015","uei":null,"lei":null,"duns":null,"ticker":"IONS"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","open.payments","dol.form5500","hud.housing","irs.bmf"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"fda":1,"sec":54,"clinical":7},"count":62,"timeline":[{"ts":"20260703","kind":"fda.label","reporter":"Ionis Pharmaceuticals, Inc.","title":"TRYNGOLZA","security_title":"OLEZARSEN SODIUM","excerpt":"1 INDICATIONS AND USAGE TRYNGOLZA ® is indicated as an adjunct to diet: To reduce triglycerides (TG) in adults with familial chylomicronemia syndrome (FCS). To reduce TG and the risk of acute pancreat","accession_number":"0f51aa8e-8475-8cf9-e063-6394a90a6848","route":"SUBCUTANEOUS","product_type":"HUMAN PRESCRIPTION DRUG","importance":30},{"ts":"2026-07-15","kind":"sec.insider.m","reporter":"BERTHELSEN SPENCER R","title":null,"shares":5220,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-07-15","kind":"sec.insider.m","reporter":"HERMAN JOAN E","title":null,"shares":5220,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-07-09","kind":"sec.filing","form_type":"8-K","title":"8-K — IONIS PHARMACEUTICALS INC — 2026-07-09","url_slug":"/sec/cik-0000874015/8-k/0001140361-26-028092","accession_number":"0001140361-26-028092","importance":35},{"ts":"2026-07-07","kind":"sec.form144","reporter":"BENNETT C FRANK","title":"Officer","shares":67386,"usd_value":5724724,"security_title":"Common Stock","approx_sale_date":"2026-07-07","accession_number":"0001972481-26-000225","importance":41.1449448},{"ts":"2026-07-07","kind":"sec.form144","reporter":"Diaz Allene M.","title":"Director","shares":10111,"usd_value":863637,"security_title":"Common Stock","approx_sale_date":"2026-07-07","accession_number":"0001972481-26-000227","importance":40.1727274},{"ts":"2026-07-07","kind":"sec.form144","reporter":"Kordasiewicz Holly B.","title":"Officer","shares":1287,"usd_value":108494,"security_title":"Common Stock","approx_sale_date":"2026-07-07","accession_number":"0001972481-26-000226","importance":40.0216988},{"ts":"2026-07-07","kind":"sec.insider.s","reporter":"BENNETT C FRANK","title":"EVP, Chief Scientific Officer","shares":15000,"price_per_share":85.462,"usd_value":1281930,"security_title":"Common Stock","importance":36.28193},{"ts":"2026-07-07","kind":"sec.insider.s","reporter":"Diaz Allene M.","title":null,"shares":10111,"price_per_share":85.4156,"usd_value":863637,"security_title":"Common Stock","importance":35.8636371316},{"ts":"2026-07-07","kind":"sec.insider.s","reporter":"BENNETT C FRANK","title":"EVP, Chief Scientific Officer","shares":5536,"price_per_share":83.579,"usd_value":462693,"security_title":"Common Stock","importance":35.462693344},{"ts":"2026-07-07","kind":"sec.insider.s","reporter":"Kordasiewicz Holly B.","title":"EVP, Chief Development Officer","shares":362,"price_per_share":84.3,"usd_value":30517,"security_title":"Common Stock","importance":35.0305166},{"ts":"2026-07-07","kind":"sec.insider.m","reporter":"Diaz Allene M.","title":null,"shares":10111,"price_per_share":47.11,"usd_value":476329,"security_title":"Common Stock","importance":15.47632921},{"ts":"2026-07-07","kind":"sec.insider.j","reporter":"BENNETT C FRANK","title":"EVP, Chief Scientific Officer","shares":15000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-07-01","kind":"sec.form144","reporter":"KLEIN JOSEPH III","title":"Director","shares":11518,"usd_value":910417,"security_title":"Common Stock","approx_sale_date":"2026-07-01","accession_number":"0001972481-26-000222","importance":40.1820834},{"ts":"2026-07-01","kind":"sec.insider.s","reporter":"KLEIN JOSEPH III","title":null,"shares":11419,"price_per_share":79.0394,"usd_value":902551,"security_title":"Common Stock","importance":35.9025509086},{"ts":"2026-07-01","kind":"sec.insider.s","reporter":"KLEIN JOSEPH III","title":null,"shares":99,"price_per_share":79.45,"usd_value":7866,"security_title":"Common Stock","importance":35.00786555},{"ts":"2026-07-01","kind":"sec.insider.m","reporter":"KLEIN JOSEPH III","title":null,"shares":11518,"price_per_share":39.94,"usd_value":460029,"security_title":"Common Stock","importance":15.46002892},{"ts":"2026-06-26","kind":"sec.form144","reporter":"Baroldi Mariana","title":"Member of immediate family of any of the foregoing","shares":5635,"usd_value":451699,"security_title":"Common Stock","approx_sale_date":"2026-06-26","accession_number":"0001972481-26-000215","importance":40.0903398},{"ts":"2026-06-26","kind":"sec.form144","reporter":"O'NEIL PATRICK R.","title":"Officer","shares":3069,"usd_value":245520,"security_title":"Common Stock","approx_sale_date":"2026-06-26","accession_number":"0001972481-26-000214","importance":40.049104},{"ts":"2026-06-26","kind":"sec.insider.s","reporter":"Monia Brett P","title":"Chief Executive Officer","shares":50000,"price_per_share":80.59,"usd_value":4029500,"security_title":"Common Stock","importance":39.0295},{"ts":"2026-06-26","kind":"sec.insider.s","reporter":"Schneider Eugene","title":"EVP, Chf Clinical Develop Ofcr","shares":26000,"price_per_share":81.046,"usd_value":2107196,"security_title":"Common Stock","importance":37.107196},{"ts":"2026-06-26","kind":"sec.insider.s","reporter":"Baroldi Joseph","title":"EVP, Chief Business Officer","shares":5635,"price_per_share":80.1595,"usd_value":451699,"security_title":"Common Stock","importance":35.4516987825},{"ts":"2026-06-26","kind":"sec.insider.s","reporter":"O'NEIL PATRICK R.","title":"EVP CLO & General Counsel","shares":3069,"price_per_share":80,"usd_value":245520,"security_title":"Common Stock","importance":35.24552},{"ts":"2026-06-26","kind":"sec.insider.m","reporter":"Monia Brett P","title":"Chief Executive Officer","shares":50000,"price_per_share":56.78,"usd_value":2839000,"security_title":"Common Stock","importance":17.839},{"ts":"2026-06-26","kind":"sec.insider.m","reporter":"Schneider Eugene","title":"EVP, Chf Clinical Develop Ofcr","shares":26000,"price_per_share":60.89,"usd_value":1583140,"security_title":"Common Stock","importance":16.58314},{"ts":"2026-06-26","kind":"sec.insider.m","reporter":"Baroldi Joseph","title":"EVP, Chief Business Officer","shares":3866,"price_per_share":56.78,"usd_value":219511,"security_title":"Common Stock","importance":15.21951148},{"ts":"2026-06-26","kind":"sec.insider.m","reporter":"Baroldi Joseph","title":"EVP, Chief Business Officer","shares":1769,"price_per_share":32.6,"usd_value":57669,"security_title":"Common Stock","importance":15.0576694},{"ts":"2026-06-25","kind":"sec.form144","reporter":"Swayze Eric","title":"Officer","shares":10602,"usd_value":839287,"security_title":"Common Stock","approx_sale_date":"2026-06-25","accession_number":"0001972481-26-000211","importance":40.1678574},{"ts":"2026-06-25","kind":"sec.insider.s","reporter":"Monia Brett P","title":"Chief Executive Officer","shares":21072,"price_per_share":78.49,"usd_value":1653941,"security_title":"Common Stock","importance":36.65394128},{"ts":"2026-06-25","kind":"sec.insider.s","reporter":"Swayze Eric","title":"EVP Research","shares":10602,"price_per_share":79.1824,"usd_value":839492,"security_title":"Common Stock","importance":35.8394918048},{"ts":"2026-06-25","kind":"sec.insider.m","reporter":"Monia Brett P","title":"Chief Executive Officer","shares":21072,"price_per_share":32.6,"usd_value":686947,"security_title":"Common Stock","importance":15.6869472},{"ts":"2026-06-24","kind":"sec.insider.s","reporter":"Monia Brett P","title":"Chief Executive Officer","shares":14565,"price_per_share":78.4128,"usd_value":1142082,"security_title":"Common Stock","importance":36.142082432},{"ts":"2026-06-24","kind":"sec.filing","form_type":"8-K","title":"8-K — IONIS PHARMACEUTICALS INC — 2026-06-24","url_slug":"/sec/cik-0000874015/8-k/0001140361-26-026232","accession_number":"0001140361-26-026232","importance":35},{"ts":"2026-06-24","kind":"sec.insider.m","reporter":"Monia Brett P","title":"Chief Executive Officer","shares":14565,"price_per_share":32.6,"usd_value":474819,"security_title":"Common Stock","importance":15.474819},{"ts":"2026-06-16","kind":"sec.filing","form_type":"4","title":"4 — Kordasiewicz Holly B. — 2026-06-16","url_slug":"/sec/cik-0002102721/4/0000874015-26-000208","accession_number":"0000874015-26-000208","importance":30},{"ts":"2026-06-15","kind":"sec.form144","reporter":"BERTHELSEN SPENCER R","title":"Director","shares":8000,"usd_value":587920,"security_title":"Common","approx_sale_date":"2026-06-15","accession_number":"0001959173-26-004629","importance":40.117584},{"ts":"2026-06-15","kind":"sec.insider.s","reporter":"BERTHELSEN SPENCER R","title":null,"shares":8000,"price_per_share":73.49,"usd_value":587920,"security_title":"Common Stock","importance":35.58792},{"ts":"2026-06-15","kind":"sec.insider.m","reporter":"BERTHELSEN SPENCER R","title":null,"shares":8000,"price_per_share":24.42,"usd_value":195360,"security_title":"Common Stock","importance":15.19536},{"ts":"2026-06-12","kind":"sec.form144","reporter":"Kordasiewicz Holly B.","title":"Officer","shares":60846,"usd_value":4466425,"security_title":"Common Stock","approx_sale_date":"2026-06-12","accession_number":"0001972481-26-000192","importance":40.893285},{"ts":"2026-06-12","kind":"sec.insider.s","reporter":"Kordasiewicz Holly B.","title":"EVP, Chief Development Officer","shares":41004,"price_per_share":73.0934,"usd_value":2997122,"security_title":"Common Stock","importance":37.9971217736},{"ts":"2026-06-12","kind":"sec.insider.s","reporter":"Kordasiewicz Holly B.","title":"EVP, Chief Development Officer","shares":19842,"price_per_share":74.0503,"usd_value":1469306,"security_title":"Common Stock","importance":36.4693060526},{"ts":"2026-06-12","kind":"sec.filing","form_type":"8-K","title":"8-K — IONIS PHARMACEUTICALS INC — 2026-06-12","url_slug":"/sec/cik-0000874015/8-k/0001140361-26-025050","accession_number":"0001140361-26-025050","importance":35},{"ts":"2026-06-12","kind":"sec.insider.m","reporter":"Kordasiewicz Holly B.","title":"EVP, Chief Development Officer","shares":21000,"price_per_share":60.89,"usd_value":1278690,"security_title":"Common Stock","importance":16.27869},{"ts":"2026-06-12","kind":"sec.insider.m","reporter":"Kordasiewicz Holly B.","title":"EVP, Chief Development Officer","shares":19895,"price_per_share":56.78,"usd_value":1129638,"security_title":"Common Stock","importance":16.1296381},{"ts":"2026-06-12","kind":"sec.insider.m","reporter":"Kordasiewicz Holly B.","title":"EVP, Chief Development Officer","shares":7951,"price_per_share":60.89,"usd_value":484136,"security_title":"Common Stock","importance":15.48413639},{"ts":"2026-06-12","kind":"sec.insider.m","reporter":"Kordasiewicz Holly B.","title":"EVP, Chief Development Officer","shares":12000,"price_per_share":32.6,"usd_value":391200,"security_title":"Common Stock","importance":15.3912},{"ts":"2026-06-08","kind":"sec.filing","form_type":"8-K","title":"8-K — IONIS PHARMACEUTICALS INC — 2026-06-08","url_slug":"/sec/cik-0000874015/8-k/0001140361-26-024407","accession_number":"0001140361-26-024407","importance":35},{"ts":"2026-06-01","kind":"sec.form144","reporter":"BERTHELSEN SPENCER R","title":"Director","shares":8000,"usd_value":605360,"security_title":"Common","approx_sale_date":"2026-06-01","accession_number":"0001959173-26-004164","importance":40.121072},{"ts":"2026-06-01","kind":"sec.insider.s","reporter":"BERTHELSEN SPENCER R","title":null,"shares":8000,"price_per_share":75.67,"usd_value":605360,"security_title":"Common Stock","importance":35.60536},{"ts":"2026-06-01","kind":"sec.insider.m","reporter":"BERTHELSEN SPENCER R","title":null,"shares":8000,"price_per_share":24.42,"usd_value":195360,"security_title":"Common Stock","importance":15.19536},{"ts":"2026-05-15","kind":"clinical.trial","reporter":"Ionis Pharmaceuticals, Inc.","title":"REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06914609","excerpt":"[\"Angelman Syndrome\"]","importance":60},{"ts":"2026-05-14","kind":"sec.insider.s","reporter":"Monia Brett P","title":"Chief Executive Officer","shares":3220,"price_per_share":78.6793,"usd_value":253347,"security_title":"Common Stock","importance":35.253347346},{"ts":"2026-05-14","kind":"sec.insider.m","reporter":"Monia Brett P","title":"Chief Executive Officer","shares":3220,"price_per_share":32.6,"usd_value":104972,"security_title":"Common Stock","importance":15.104972},{"ts":"2026-05-13","kind":"sec.form144","reporter":"Monia Brett P","title":"Officer","shares":100000,"usd_value":7801300,"security_title":"Common Stock","approx_sale_date":"2026-05-13","accession_number":"0001972481-26-000157","importance":41.56026},{"ts":"2026-05-13","kind":"sec.insider.s","reporter":"Monia Brett P","title":"Chief Executive Officer","shares":1316,"price_per_share":78.013,"usd_value":102665,"security_title":"Common Stock","importance":35.102665108},{"ts":"2026-05-13","kind":"sec.insider.m","reporter":"Monia Brett P","title":"Chief Executive Officer","shares":1316,"price_per_share":32.6,"usd_value":42902,"security_title":"Common Stock","importance":15.0429016},{"ts":"2026-05-08","kind":"clinical.trial","reporter":"Ionis Pharmaceuticals, Inc.","title":"An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary Angioedema","security_title":"PHASE2","status":"COMPLETED","accession_number":"NCT04307381","excerpt":"[\"Hereditary Angioedema\"]","importance":45},{"ts":"2026-05-04","kind":"clinical.trial","reporter":"Ionis Pharmaceuticals, Inc.","title":"ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT07531745","excerpt":"[\"Dravet Syndrome\"]","importance":45},{"ts":"2026-04-29","kind":"clinical.trial","reporter":"Ionis Pharmaceuticals, Inc.","title":"Donidalorsen Treatment in Children With Hereditary Angioedema","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07298447","excerpt":"[\"Hereditary Angioedema (HAE)\"]","importance":60},{"ts":"2026-04-27","kind":"clinical.trial","reporter":"Ionis Pharmaceuticals, Inc.","title":"Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT04165486","excerpt":"[\"Multiple System Atrophy\"]","importance":30},{"ts":"2026-04-23","kind":"clinical.trial","reporter":"Ionis Pharmaceuticals, Inc.","title":"A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia","security_title":"PHASE2","status":"COMPLETED","accession_number":"NCT05355402","excerpt":"[\"Hypertriglyceridemia\",\"Atherosclerotic Cardiovascular Disease\",\"Severe Hypertriglyceridemia\"]","importance":45},{"ts":"2026-04-17","kind":"clinical.trial","reporter":"Ionis Pharmaceuticals, Inc.","title":"An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)","security_title":"PHASE3","status":"ENROLLING_BY_INVITATION","accession_number":"NCT05667493","excerpt":"[\"Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)\"]","importance":60}]}